Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Eli Lilly And Novo Nordisk Could Face Policy Shifts As FDA Oversight, Tariff Risks Mount
02:50pm, Monday, 07'th Apr 2025
Needham hosted Spencer Perlman, director of Healthcare Research at Veda Partners, an investment advisory and consulting firm with extensive expertise in government policy analysis. During the conversa
NVO & LLY Shares Down on Exclusion of Obesity Drugs From Medicare
10:47am, Monday, 07'th Apr 2025
CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they are solely prescribed for weight loss.
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
09:40am, Monday, 07'th Apr 2025
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
2 Top Growth Stocks to Buy and Hold for the Next 20 Years
08:00am, Sunday, 06'th Apr 2025
One of the keys to successful investing is holding shares of companies that can perform well over long periods. However, few companies can thrive for that long while delivering excellent returns to in
3 Dividend Stocks to Buy and Hold for the Next Decade
06:44am, Sunday, 06'th Apr 2025
What should investors do when stocks are tanking over the short term? Probably the best answer is to think long term.
Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss Drugs
05:55pm, Friday, 04'th Apr 2025
The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.
Trump drops Biden's proposal for Medicare to cover obesity drugs like Wegovy and Zepbound
05:34pm, Friday, 04'th Apr 2025
President Donald Trump dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular GLP-1 treatments such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. But th
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal
02:57pm, Friday, 04'th Apr 2025
Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payme
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
01:01pm, Friday, 04'th Apr 2025
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
These 5 S&P 500 Stocks Are Growing Revenue The Most Right Now
11:49am, Friday, 04'th Apr 2025
These 5 companies will have minimal impact from the tariffs and could deliver strong results in 2025.
PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
10:46am, Wednesday, 02'nd Apr 2025
Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.
Why April Could Be a Huge Month for Eli Lilly Stock
06:46am, Wednesday, 02'nd Apr 2025
Eli Lilly (LLY -2.70%) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 months, however, the stock's performance has been fairly lackluster, rising
Altria vs. Eli Lilly: What's the Better Stock for Dividend Investors?
05:06am, Wednesday, 02'nd Apr 2025
Tobacco giant Altria (MO -1.77%) provides a tremendously high dividend yield of 7%, which is well above the S&P 500 index average of 1.3%. But it comes with risks, as its business has been struggling
Hims & Hers shares rise as company adds Eli Lilly's Zepbound
07:44pm, Tuesday, 01'st Apr 2025
CNBC's Brandon Gomez joins 'Closing Bell' to discuss Hims & Hers shares rising as company adds new weight-loss medications to platform.
Why Major Pharmaceutical Stocks Tumbled on Tuesday
07:09pm, Tuesday, 01'st Apr 2025
Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons. The Trump administration's promised tariffs were set to go into effect the following day,
